31 patents
Utility
Liquid nimodipine compositions
6 Dec 22
Liquid compositions comprising nimodipine having improved nimodipine concentrations are provided herein.
Hugh Greg Thomas
Filed: 30 Mar 22
Utility
Non-aqueous liquid nimodipine compositions
16 Aug 22
Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein.
Hugh Greg Thomas
Filed: 22 Dec 21
Utility
Crystalline Form of y-Aminobutyric Acid Analog
11 Aug 22
A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided.
Tono Estrada, Stephen P. Raillard, Christine Hook-Frauenfelder, Uwe Zacher
Filed: 20 Sep 21
Utility
Pharmaceutical Compositions of Fumaric Acid Esters
4 Aug 22
Pharmaceutical compositions and dosage forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate and/or methyl 4-morpholin-4-ylbutyl (2E)but-2-ene-1,4-dioate, containing low levels of certain impurities are disclosed.
Suresh Kumar Manthati, Sarni Karaborni, Wei Chen
Filed: 3 Sep 21
Utility
Liquid Nimodipine Compositions
14 Jul 22
Liquid compositions comprising nimodipine having improved nimodipine concentrations are provided herein.
Hugh Greg Thomas
Filed: 30 Mar 22
Utility
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice
26 May 22
An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis).
Nicholas Spring, Garry T. Gwozdz
Filed: 8 Feb 22
Utility
Non-Aqueous Liquid Nimodipine Compositions
14 Apr 22
Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein.
Hugh Greg Thomas
Filed: 22 Dec 21
Utility
Non-Aqueous Liquid Nimodipine Compositions
14 Apr 22
Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein.
Hugh Greg Thomas
Filed: 22 Dec 21
Utility
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice
31 Mar 22
An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis).
Nicholas Spring, Garry T. Gwozdz
Filed: 13 Dec 21
Utility
Non-Aqueous Liquid Nimodipine Compositions
10 Mar 22
Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein.
Hugh Greg Thomas
Filed: 19 Nov 21
Utility
Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice
25 Jan 22
An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis).
Nicholas Spring, Garry T. Gwozdz
Filed: 20 Mar 20
Utility
Pharmaceutical compositions of dimethyl fumarate
25 Jan 22
Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed.
Sami Karaborni, Wei Chen, Suresh Kumar Manthati
Filed: 22 Jan 20
Utility
Non-aqueous liquid nimodipine compositions
28 Dec 21
Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein.
Hugh Greg Thomas
Filed: 20 Dec 19
Utility
Pharmaceutical compositions of fumaric acid esters
5 Oct 21
Pharmaceutical compositions and dosage forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate and/or methyl 4-morpholin-4-ylbutyl (2E)but-2-ene-1,4-dioate, containing low levels of certain impurities are disclosed.
Suresh Kumar Manthati, Sami Karaborni, Wei Chen
Filed: 15 May 18
Utility
Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
29 Jul 21
Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
Kenneth C. Cundy, Sami Karaborni, Peter A. Virsik
Filed: 3 Feb 21
Utility
Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate
17 Jun 21
Improved methods of treating multiple sclerosis and/or psoriasis using prodrugs of methyl hydrogen fumarate are disclosed.
Peter Virsik, David Wustrow, Thamil Annamalai, Suresh Manthati
Filed: 1 Mar 21
Utility
Sotalol compositions and uses of the same
25 May 21
The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability.
H. Greg Thomas, Jeffrey S. Kiel
Filed: 9 Jan 19
Utility
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
20 May 21
Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed.
Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David Wustrow, Peter Virsik
Filed: 27 Jan 21
Utility
Sotalol Compositions and Uses of the Same
18 Mar 21
The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability.
H. Greg Thomas, Jeffrey S. Kiel
Filed: 29 Sep 20
Utility
Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
16 Mar 21
Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
Kenneth C. Cundy, Sami Karaborni, Peter A. Virsik
Filed: 22 Aug 13